ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes - Takeaways - MDSpire

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

  • By

  • Shaoqing Yin

  • Jiaye Li

  • Wei Zhang

  • Rui Ding

  • Yan Li

  • Kai Wang

  • Wenjian Jiang

  • Yi-Da Tang

  • Zhengjun Yi

  • Yaohua Zhang

  • Meng Li

  • June 17, 2026

  • 0 min

Share

  • 1

    ABO blood group antigens are crucial genetic determinants influencing disease susceptibility and drug response.

  • 2

    Polymorphisms in the ABO gene affect glycosyltransferases, leading to varying risks for cancers and cardiovascular diseases.

  • 3

    Non-O blood groups are linked to higher incidences of certain cancers and increased levels of von Willebrand factor.

  • 4

    ABO blood type impacts drug efficacy, with type O individuals requiring lower doses of warfarin compared to non-O individuals.

  • 5

    Integrating ABO typing into clinical practice could enhance personalized medicine by improving risk assessment and treatment strategies.

Original Source(s)

ABO gene polymorphisms: a molecular bridge linking disease susceptibility to therapeutic outcomes

  • by Shaoqing Yin, Jiaye Li, Wei Zhang, Rui Ding, Yan Li, Kai Wang, Wenjian Jiang, Yi-Da Tang, Zhengjun Yi, Yaohua Zhang, Meng Li

  • June 17, 2026

Related Content

Biology of p53 protein isoforms and their significance in hematological malignancies

Nonprofit buys experimental cancer drug to maintain patient access

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis